Cite
HARVARD Citation
Soubrier, M. et al. (n.d.). SAT0117 Retention rates of adalimumab, etanercept, and infliximab as 1st- or 2nd-line biotherapy for rheumatoid arthritis patients in daily practice in auvergne. Annals of the rheumatic diseases. p. 813. [Online].